Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,otherCurrentAssets,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,priceHint,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,country,website,maxAge,address1,industry,address2
t0,GTSIF,1459491.0,199734000,165072,,-1245192,,-1245192,1041349,171176,-1249694,-1249694,,-7261,,,,0,180618,1430312,9442,4502,,-1245192,-1245192,11012207.0,1163962.0,441311.0,12471698.0,64825.0,12913009.0,19963588.0,-10060955.0,1405103.0,144559.0,107091.0,371281.0,1405103.0,485027.0,1271216.0,58868.0,664779.0,156960.0,,-402740.0,-44070.0,1519704.0,-121770.0,1684747.0,-65016.0,943.0,-1585663.0,137338.0,-44593.0,-120973.0,91294.0,,899935.0,en-US,US,EQUITY,False,Delayed Quote,-5.1358023,0.0502 - 0.06,0.0567,finmb_569918770,Other OTC,Lobe Sciences Ltd.,CAD,277252,148171,0.028687999,1.1429482,0.0251 - 0.22,-0.16621199,-0.7555091,0.0251,0.22,USD,4,0.065265276,-0.011477277,-0.17585579,0.1002786,-0.046490602,-0.46361437,10743292,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.053788,1630519393,-0.0029119998,0.0502,0.06,0.0502,69036,LOBE SCIENCES LTD,us_market,PREPRE,3.99,,,0.22,0.0251,0.0653,0.1003,277.25k,148.17k,199.73M,,181.83M,11.24%,2.75%,,,,,,,,,,,0.00%,,,,,"Aug 30, 2020","Nov 29, 2020",0.00%,-438.92%,-24.78%,-43.63%,888.53k,0.01,2.10%,841.56k,-3.77M,-4M,,,165.96k,0,256.86k,2.06,3.42,,-2.45M,-1.24M,Value,V6B 2Z4,Healthcare,"Lobe Sciences Ltd., a technology and services company, provides real estate, financial, management, intellectual property, and branding support for development of transformational medicine in the United States. The company intends to develop psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications. It also owns acquired brands, intellectual property, and leases office and production premises to a cannabis processor and retailer. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.",Vancouver,604 834 9499,BC,Canada,http://www.lobesciences.com,86400,422 Richards Street,Drug Manufacturers—Specialty & Generic,Suite 170
t-1,GTSIF,988233.0,199734000,165072,,-1435596,,-1435596,641571,171358,-1355777,-1355777,,-8277,,,,0,181404,1537181,10046,-79819,,-1435596,-1435596,11085773.0,1163962.0,897086.0,12074006.0,65210.0,12971092.0,18524509.0,-8815763.0,1201298.0,143462.0,172107.0,776883.0,1201298.0,571421.0,1170436.0,,621206.0,376798.0,8425.0,229344.0,-44589.0,543789.0,-358053.0,585000.0,127813.0,943.0,-614716.0,140605.0,29059.0,3378.0,779925.0,198740.0,393553.0,en-US,US,EQUITY,False,Delayed Quote,-5.1358023,0.0502 - 0.06,0.0567,finmb_569918770,Other OTC,Lobe Sciences Ltd.,CAD,277252,148171,0.028687999,1.1429482,0.0251 - 0.22,-0.16621199,-0.7555091,0.0251,0.22,USD,4,0.065265276,-0.011477277,-0.17585579,0.1002786,-0.046490602,-0.46361437,10743292,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.053788,1630519393,-0.0029119998,0.0502,0.06,0.0502,69036,LOBE SCIENCES LTD,us_market,PREPRE,3.99,,,0.22,0.0251,0.0653,0.1003,277.25k,148.17k,199.73M,,181.83M,11.24%,2.75%,,,,,,,,,,,0.00%,,,,,"Aug 30, 2020","Nov 29, 2020",0.00%,-438.92%,-24.78%,-43.63%,888.53k,0.01,2.10%,841.56k,-3.77M,-4M,,,165.96k,0,256.86k,2.06,3.42,,-2.45M,-1.24M,Value,V6B 2Z4,Healthcare,"Lobe Sciences Ltd., a technology and services company, provides real estate, financial, management, intellectual property, and branding support for development of transformational medicine in the United States. The company intends to develop psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications. It also owns acquired brands, intellectual property, and leases office and production premises to a cannabis processor and retailer. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.",Vancouver,604 834 9499,BC,Canada,http://www.lobesciences.com,86400,422 Richards Street,Drug Manufacturers—Specialty & Generic,Suite 170
t-2,GTSIF,1545547.0,199734000,165072,,-318001,,-318001,146989,219435,-304416,-304416,,-11043,,,,0,230772,535188,11337,-13585,,-318001,-318001,3967417.0,1250324.0,848360.0,5512964.0,68935.0,6361324.0,9997347.0,-7151741.0,1417034.0,499536.0,44294.0,622507.0,1417034.0,388579.0,1505792.0,,1442428.0,254320.0,,36988.0,-41901.0,-41901.0,13083.0,585000.0,-114584.0,-34028.0,-38655.0,146964.0,-156804.0,3378.0,239115.0,198740.0,883285.0,en-US,US,EQUITY,False,Delayed Quote,-5.1358023,0.0502 - 0.06,0.0567,finmb_569918770,Other OTC,Lobe Sciences Ltd.,CAD,277252,148171,0.028687999,1.1429482,0.0251 - 0.22,-0.16621199,-0.7555091,0.0251,0.22,USD,4,0.065265276,-0.011477277,-0.17585579,0.1002786,-0.046490602,-0.46361437,10743292,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.053788,1630519393,-0.0029119998,0.0502,0.06,0.0502,69036,LOBE SCIENCES LTD,us_market,PREPRE,3.99,,,0.22,0.0251,0.0653,0.1003,277.25k,148.17k,199.73M,,181.83M,11.24%,2.75%,,,,,,,,,,,0.00%,,,,,"Aug 30, 2020","Nov 29, 2020",0.00%,-438.92%,-24.78%,-43.63%,888.53k,0.01,2.10%,841.56k,-3.77M,-4M,,,165.96k,0,256.86k,2.06,3.42,,-2.45M,-1.24M,Value,V6B 2Z4,Healthcare,"Lobe Sciences Ltd., a technology and services company, provides real estate, financial, management, intellectual property, and branding support for development of transformational medicine in the United States. The company intends to develop psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications. It also owns acquired brands, intellectual property, and leases office and production premises to a cannabis processor and retailer. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.",Vancouver,604 834 9499,BC,Canada,http://www.lobesciences.com,86400,422 Richards Street,Drug Manufacturers—Specialty & Generic,Suite 170
t-3,GTSIF,1671914.0,199734000,165072,,-999202,,-999202,666695,284799,-990058,-990058,,-11370,,,,0,295737,1285795,10938,-9144,,-999202,-999202,3918555.0,1250324.0,837756.0,5590469.0,201435.0,6428225.0,9997347.0,-6833740.0,1176538.0,661479.0,158878.0,571705.0,1176538.0,423908.0,1424283.0,,1240770.0,259958.0,,33735.0,-38486.0,101514.0,360870.0,140000.0,-112184.0,-2939.0,-210759.0,136503.0,-202587.0,3378.0,459922.0,198740.0,852578.0,en-US,US,EQUITY,False,Delayed Quote,-5.1358023,0.0502 - 0.06,0.0567,finmb_569918770,Other OTC,Lobe Sciences Ltd.,CAD,277252,148171,0.028687999,1.1429482,0.0251 - 0.22,-0.16621199,-0.7555091,0.0251,0.22,USD,4,0.065265276,-0.011477277,-0.17585579,0.1002786,-0.046490602,-0.46361437,10743292,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.053788,1630519393,-0.0029119998,0.0502,0.06,0.0502,69036,LOBE SCIENCES LTD,us_market,PREPRE,3.99,,,0.22,0.0251,0.0653,0.1003,277.25k,148.17k,199.73M,,181.83M,11.24%,2.75%,,,,,,,,,,,0.00%,,,,,"Aug 30, 2020","Nov 29, 2020",0.00%,-438.92%,-24.78%,-43.63%,888.53k,0.01,2.10%,841.56k,-3.77M,-4M,,,165.96k,0,256.86k,2.06,3.42,,-2.45M,-1.24M,Value,V6B 2Z4,Healthcare,"Lobe Sciences Ltd., a technology and services company, provides real estate, financial, management, intellectual property, and branding support for development of transformational medicine in the United States. The company intends to develop psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications. It also owns acquired brands, intellectual property, and leases office and production premises to a cannabis processor and retailer. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.",Vancouver,604 834 9499,BC,Canada,http://www.lobesciences.com,86400,422 Richards Street,Drug Manufacturers—Specialty & Generic,Suite 170
